The Presence of Hla-directed Antibodies after Heart Transplantation Is Associated with Poor Allograft Outcome
2005
Background. The clinical significance of
HLA-directed antibodies newly detected after transplantation (HT) is controversial. Methods. Seventy-one HT recipients consented to enroll. Mean follow-up time was 28 months (range 6-48).
Panel reactive antibody(PRA) analysis was performed on posttransplant sera (2 weeks, 1, 2, 3, 6, and 12 months and annually thereafter) using Flow-PRA. A mean of 6.9 ± 1.2 serum samples per patient were obtained. Severity of cellular rejection was measured using the ISHLT grading system. Coronary angiography and
intravascular ultrasound(IVUS) studies were performed annually to evaluate severity of allograft vasculopathy. Results. Twenty-five recipients had newly detected
HLA-directed antibodies during the first year postHT.
HLAclass I antibodies were detected in 18 patients (25.4%), and class II in 11 patients (15.5%). The majority of donor recipient pairs were
HLAmismatched (4.6 ± 1.2 of the six major
HLAantigens). Only mismatches at
HLA-A locus had significant association with de novo posttransplant antibody formation. Length of ischemia time was correlated with early and sustained presence of de novo
HLA-directed antibodies postheart transplant. Importantly, an association between de novo
HLA-directed antibodies and cellular rejection was notes (P=0.0002). De novo
HLAclass II directed antibodies are also associated with IVUS documented vasculopathy (P<0.002). Finally, death due to allograft failure is associated with the presence of de novo formed
HLAclass II directed antibodies (P=0.008). Conclusions. Identifying the formation of de novo
HLA-directed antibodies following
heart transplantationmay predict allograft outcome. This, in turn, may serve as a tool for individualization of immunosuppression protocols in
heart transplantrecipients.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
17
References
139
Citations
NaN
KQI